NewsBite

CVC's Bionomics board push falters as cancer drug trial kicks off

Tim BinstedReporter
Updated

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Activist investor CVC is backing away from plans to muscle directors onto the board of Bionomics after failing to garner support from other shareholders in the biotechnology company.

CVC, owner of 5 per cent of Bionomics, said last month that it would call a meeting to oust Bionomics chairman Graeme Kaufman and director Trevor Tappenden, while signalling its intent to nominate CVC chief executive Sandy Beard and fellow dissident investor Laurence Freedman as directors.

Loading...
Tim Binsted writes on Business specialising in Agriculture, Construction, Manufacturing. Tim is based in our Sydney newsroom. Connect with Tim on Twitter.

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Read More

Latest In Equity markets

Fetching latest articles

Most Viewed In Markets

    Original URL: https://www.afr.com/markets/equity-markets/cvcs-bionomics-board-push-falters-as-cancer-drug-trial-kicks-off-20160403-gnwzx4